Skip to main navigation
Skip to search
Skip to main content
Research Profiles at Washington University School of Medicine Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Novel anticoagulants and laboratory testing
C. Eby
Division of Laboratory and Genomic Medicine
Institute of Clinical and Translational Sciences (ICTS)
Research output
:
Contribution to journal
›
Review article
›
peer-review
42
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Novel anticoagulants and laboratory testing'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Laboratory Testing
100%
Anticoagulant Testing
100%
Novel Anticoagulants
100%
Coagulation
66%
Clinical Practice
33%
Result Interpretation
33%
New Anticoagulants
33%
Accurate Interpretation
33%
Appropriate Testing
33%
Dabigatran
33%
Rivaroxaban
33%
Adverse Event Management
33%
Therapeutic Drug Monitoring
33%
Anticoagulant Activity
33%
Coagulation Tests
33%
Apixaban
33%
Direct Oral Anticoagulants
33%
Oral Factor Xa Inhibitors
33%
Oral Direct Thrombin Inhibitor
33%
Neuroscience
Blood Clotting Factor 10a
100%
Antithrombotic
100%
Anticoagulant
100%
Direct Thrombin Inhibitor
100%
Dabigatran
100%
Rivaroxaban
100%
Apixaban
100%
Blood Plasma
100%
Medicine and Dentistry
Laboratory Test
100%
Anticoagulant
100%
Diagnosis
33%
Adverse Event
33%
Anticoagulation
33%
Therapeutic Drug Monitoring
33%
Direct Thrombin Inhibitor
33%
Dabigatran
33%
Rivaroxaban
33%
Blood Clotting Test
33%
Direct Oral Anticoagulant
33%
Apixaban
33%
Blood Clotting Factor 10a Inhibitor
33%
Nursing and Health Professions
Laboratory Test
100%
Anticoagulant Agent
100%
Diagnosis
33%
Adverse Event
33%
Anticoagulation
33%
Clinical Practice
33%
Therapeutic Drug Monitoring
33%
Blood Clotting Test
33%
Apixaban
33%
Rivaroxaban
33%
Blood Clotting Factor 10a Inhibitor
33%
Dabigatran
33%
Thrombin Inhibitor
33%
Pharmacology, Toxicology and Pharmaceutical Science
Anticoagulant Agent
100%
Adverse Event
50%
Therapeutic Drug Monitoring
50%
Blood Clotting Factor 10a Inhibitor
50%
Thrombin Inhibitor
50%
Rivaroxaban
50%
Dabigatran
50%
Direct Oral Anticoagulant
50%
Apixaban
50%
Anticoagulant Activity
50%